Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-AZA and ATRA for Recurrent Prostate Cancer
NCT03572387Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Aug 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of azacitidine and tretinoin in prostate cancer (PCa) (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Number of Participants With PSA Response at 24 weeks and Safety and Adverse Events at 24 weeks. Started Aug 2018; status: completed.
02
Drugs
azacitidinetretinoin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03572387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572387.